2004
Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly
Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer 2004, 101: 1733-1744. PMID: 15386339, DOI: 10.1002/cncr.20572.Peer-Reviewed Original ResearchConceptsAdvanced nonsmall cell lung carcinomaNonsmall cell lung carcinomaNovel biologic agentsElderly patientsCell lung carcinomaConventional chemotherapyPatient ageBiologic agentsLung carcinomaClinical developmentSuch elderly patientsVascular endothelial growth factorLung carcinoma casesQuality of lifeEndothelial growth factorEpidermal growth factor receptorGrowth factor receptorAggressive chemotherapyImproved tolerabilityYounger patientsOrgan failureTherapy regimensComorbid conditionsMalignant diseaseCarcinoma cases
2003
Gefitinib: current and future status in cancer therapy.
Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy. Clinical Advances In Hematology And Oncology 2003, 1: 466-72. PMID: 16258434.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorTumor growthEGFR tyrosine kinase inhibitorsCurrent clinical development statusOngoing clinical trialsCombination of gefitinibClinical development statusCancer cell growthHost-dependent processesGrowth factor receptorHormonal therapyStandard chemotherapyBiologic agentsDisease recurrenceCell lungSolid malignanciesClinical trialsTumor cell functionsViable drug targetNovel agentsPreclinical studiesClinical developmentTumor typesGefitinibKinase inhibitors